Andrew Jenkin has been appointed general manager of GSK Consumer Healthcare ANZ, after GSK and Pfizer closed the transaction on their joint venture on Thursday.
The latest deal brings together leading medicine brands including GSK’s Sensodyne, Voltaren and Panadol with Pfizer’s Advil, Centrum and Caltrate and makes GSK Consumer Healthcare the world’s largest over-the-counter business.
Jenkin, who was previously general manager Pfizer Consumer Healthcare ANZ, will be responsible for leading the new Joint Venture business across Australia and New Zealand.
“It’s exciting to be bringing two businesses with such positive momentum
together. We have an extremely talented team and great brands, and by partnering closely with our customers and industry I believe we can have an even more positive impact on the health and wellbeing of our consumers in Australia and New Zealand,” Jenkin said.
“Although the transaction has closed globally, GSK Consumer Healthcare ANZ and Pfizer Consumer Healthcare ANZ remain separate businesses for the time being, which means there is no immediate change to the way we operate in Australia or NZ.”
Theresa Agnew, the previous area General Manager of GSK Consumer Healthcare ANZ, has moved to global head of Pain Relief for the new Joint Venture business.
GSK expects the Joint Venture to cut costs by £0.5bn annually by 2022.
“Now the deal has closed, our focus will be on completing the integration of these two businesses and leveraging their combined strength. With our portfolio of brilliant, science-based brands and strong talent and capabilities, we are well-positioned to create a world-leading consumer healthcare business with stronger sales, cash flow and contribution to earnings,” Brian McNamara, CEO, GSK Consumer Healthcare, said.
